Market Overview

UPDATE: Morgan Stanley Reiterates On CIGNA As 4Q Issues May Linger

Related CI
Cigna Foundation Awards $15M Grant to Clínica Tepeyac in Denver to Expand Diabetes Management Programs
Benzinga's Top Initiations
Health Insurers: If You Can't Beat Them, Join Them (Seeking Alpha)

In a report published Friday, Morgan Stanley analyst Andrew Schenker reiterated an Overweight rating on CIGNA (NYSE: CI), but lowered the price target from $100.00 to $93.00.

In the report, Morgan Stanley noted, “Issues CI experienced in 4Q may spill over into 2014 results. However, >$1.5B in deployable cash in FY14 and improvements in 2H14 should yield mid single-digit EPS growth. Our adjusted EPS of $7.16 reflects 6% Y/Y growth off a lower 2013 platform.”

CIGNA closed on Friday at $76.14.

Latest Ratings for CI

Sep 2015Cowen & CompanyMaintainsOutperform
Sep 2015JP MorganInitiates Coverage onOverweight
Jul 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for CI
View the Latest Analyst Ratings

Posted-In: Andrew Schenker Morgan StanleyAnalyst Color Price Target Analyst Ratings


Related Articles (CI)

Get Benzinga's Newsletters